CD274 and neoplasm: In 18 PD-L1-positive patients (≥1% of tumor cells expressing PD-L1 as a cutoff), a statistically significantly superior median PFS was observed compared to PD-L1-negative BTCs (10.4 months versus 2.3 months; HR, 0.23; 95% CI, 0.10–0.51; p < 0.001) [37].